These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 26919549

  • 1. Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients.
    Hannun P, Felipe C, Ferreira A, Sandes-Freitas T, Cristelli M, Aguiar W, Franco M, Campos E, Gerbase de Lima M, Tedesco-Silva H, Medina-Pestana J.
    Ther Drug Monit; 2016 Jun; 38(3):293-9. PubMed ID: 26919549
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine.
    Felipe CR, Oliveira NI, Hannun PG, de Paula MI, Tedesco-Silva H, Medina-Pestana JO.
    Ther Drug Monit; 2016 Feb; 38(1):64-72. PubMed ID: 26274696
    [Abstract] [Full Text] [Related]

  • 3. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A, Felipe C, Cristelli M, Viana L, Basso G, Stopa S, Mansur J, Ivani M, Bessa A, Ruppel P, Aguiar W, Campos E, Gerbase-DeLima M, Proença H, Tedesco-Silva H, Medina-Pestana J.
    Am J Nephrol; 2017 Feb; 45(6):497-508. PubMed ID: 28511172
    [Abstract] [Full Text] [Related]

  • 4. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B, Athena Study Group.
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [Abstract] [Full Text] [Related]

  • 5. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.
    Belliere J, Kamar N, Mengelle C, Allal A, Sallusto F, Doumerc N, Game X, Congy-Jolivet N, Esposito L, Debiol B, Rostaing L.
    Transpl Int; 2016 Mar; 29(3):315-22. PubMed ID: 26575959
    [Abstract] [Full Text] [Related]

  • 6. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
    Traitanon O, Mathew JM, Shetty A, Bontha SV, Maluf DG, El Kassis Y, Park SH, Han J, Ansari MJ, Leventhal JR, Mas V, Gallon L.
    PLoS One; 2019 Mar; 14(5):e0216300. PubMed ID: 31136582
    [Abstract] [Full Text] [Related]

  • 7. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ, Felipe CR, Tedesco-Silva H, Osmar Medina-Pestana J.
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [Abstract] [Full Text] [Related]

  • 8. Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation.
    Cruzado JM, Pascual J, Sánchez-Fructuoso A, Serón D, Díaz JM, Rengel M, Oppenheimer F, Hernández D, Paravisini A, Saval N, Morales JM, Evita Study Group.
    Transpl Int; 2016 Dec; 29(12):1317-1328. PubMed ID: 27648523
    [Abstract] [Full Text] [Related]

  • 9. Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor.
    Ferreira AN, Felipe CR, Cristelli M, Viana L, Mansur J, de Paula M, Wagner D, de Marco R, Gerbase-DeLima M, Proença H, Aguiar W, Medina-Pestana J, Tedesco-Silva Junior H.
    Transpl Int; 2019 Nov; 32(11):1127-1143. PubMed ID: 31278785
    [Abstract] [Full Text] [Related]

  • 10. Tacrolimus reduction with everolimus addition for calcineurin inhibitor-induced arteriolopathy in kidney allografts.
    Miura M, Higashiyama H, Fukasawa Y, Itoh Y, Tamaki T.
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():58-60. PubMed ID: 26031588
    [Abstract] [Full Text] [Related]

  • 11. Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients.
    Felipe C, Ferreira A, Bessa A, Abait T, Perez JD, Casarini DE, Medina-Pestana J, Tedesco H.
    Ther Drug Monit; 2018 Feb; 40(1):52-58. PubMed ID: 29271815
    [Abstract] [Full Text] [Related]

  • 12. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center.
    Ciancio G, Tryphonopoulos P, Gaynor JJ, Guerra G, Sageshima J, Roth D, Chen L, Kupin W, Mattiazzi A, Tueros L, Flores S, Hanson L, Powell RH, Ruiz P, Vianna R, Burke GW.
    Transplant Proc; 2016 Feb; 48(6):2006-10. PubMed ID: 27569936
    [Abstract] [Full Text] [Related]

  • 13. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus.
    Ueno P, Felipe C, Ferreira A, Cristelli M, Viana L, Mansur J, Basso G, Hannun P, Aguiar W, Tedesco Silva H, Medina-Pestana J.
    Transplantation; 2017 Apr; 101(4):844-850. PubMed ID: 27490418
    [Abstract] [Full Text] [Related]

  • 14. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study.
    Fischer L, Saliba F, Kaiser GM, De Carlis L, Metselaar HJ, De Simone P, Duvoux C, Nevens F, Fung JJ, Dong G, Rauer B, Junge G, H2304 Study Group.
    Transplantation; 2015 Jul; 99(7):1455-62. PubMed ID: 26151607
    [Abstract] [Full Text] [Related]

  • 15. The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial.
    de Sandes-Freitas TV, Pinheiro PMA, Sales MLMBO, Girão CM, Campos ÉF, Esmeraldo RM.
    Transpl Int; 2018 Dec; 31(12):1345-1356. PubMed ID: 29969826
    [Abstract] [Full Text] [Related]

  • 16. Protein kinase C inhibitor sotrastaurin in de novo liver transplant recipients: a randomized phase II trial.
    Pascher A, De Simone P, Pratschke J, Salamé E, Pirenne J, Isoneimi H, Bijarnia M, Krishnan I, Klupp J.
    Am J Transplant; 2015 May; 15(5):1283-92. PubMed ID: 25677074
    [Abstract] [Full Text] [Related]

  • 17. A Head-to-head Comparison of De Novo Sirolimus or Everolimus Plus Reduced-dose Tacrolimus in Kidney Transplant Recipients: A Prospective and Randomized Trial.
    Toniato de Rezende Freschi J, Cristelli MP, Viana LA, Ficher KN, Nakamura MR, Proença H, Dreige YC, de Marco R, de Lima MG, Foresto RD, Aguiar WF, Medina-Pestana J, Tedesco-Silva H.
    Transplantation; 2024 Jan 01; 108(1):261-275. PubMed ID: 37525373
    [Abstract] [Full Text] [Related]

  • 18. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
    Tedesco-Silva H, Felipe C, Ferreira A, Cristelli M, Oliveira N, Sandes-Freitas T, Aguiar W, Campos E, Gerbase-DeLima M, Franco M, Medina-Pestana J.
    Am J Transplant; 2015 Oct 01; 15(10):2655-64. PubMed ID: 25988935
    [Abstract] [Full Text] [Related]

  • 19. Tolerance of enteric-coated mycophenolate sodium in combination with calcineurin inhibitor in kidney transplant recipients: Polish experience.
    Gozdowska J, Urbanowicz AL, Galazka Z, Chmura A, Durlik M.
    Transplant Proc; 2011 Oct 01; 43(8):2946-9. PubMed ID: 21996197
    [Abstract] [Full Text] [Related]

  • 20. Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
    Miranda TA, Felipe CR, Santos RHN, Medina Pestana JO, Tedesco-Silva Junior H.
    Ther Drug Monit; 2020 Dec 01; 42(6):811-820. PubMed ID: 32657909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.